4
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Canaccord Genuity analyst John Newman initiated coverage on Marker Therapeutics, Inc. (NASDAQ:MRKR) with a Buy rating and announced a price target of $8. Marker Therapeutics shares closed at $1.38 on Tuesday. See how other analysts view this stock.
- Jefferies analyst Roger Song initiated …
